Table 1.
Clinical Characteristics of the ESCA Samples in TCGA
| TCGA Set (n=183) | |
|---|---|
| Gender (%) | |
| Male | 156 (85.2%) |
| Female | 27 (14.8%) |
| Age (median, range) | Unknown |
| Survival status | |
| OS-days (median, range) | 393 (0–3714) |
| OS-state (alive (%)/dead (%)) | 108 (59.1%)/75 (40.9%) |
| Stage (%) | |
| I | 18 (9.8%) |
| II | 78 (42.6%) |
| III | 55 (30.1%) |
| IV | 9 (4.9%) |
| Unknown | 23 (12.6%) |
| T (%) | |
| 0 | 1 (0.6%) |
| 1 | 31 (16.9%) |
| 2 | 43 (23.5%) |
| 3 | 86 (47.0%) |
| 4 | 5 (2.7%) |
| Unknown | 17 (9.3%) |
| M (%) | |
| 0 | 134 (73.2%) |
| 1 | 9 (4.9%) |
| Unknown | 40 (21.9%) |
| N (%) | |
| 0 | 76 (41.4%) |
| 1 | 68 (37.2%) |
| 2 | 12 (6.6%) |
| 3 | 8 (4.4%) |
| Unknown | 19 (10.4%) |
Abbreviations: TMB, tumor mutational burden; ESCA, esophageal cancer; CNV, copy number variation; CTL, cytotoxic T lymphocyte; GO, Gene Ontology analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; NES, normalized enrichment score; IC50, maximum half inhibitory concentration; GDSC, Cancer Drug Sensitivity Genomics; ICIS, immune checkpoint inhibitors; TFH, follicular helper T cells; PD-1, programmed cell death protein 1.